# A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis

> **NCT06028438** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 103 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** Placebo
- **DRUG:** Nipocalimab
- **DRUG:** Certolizumab

## Key facts

- **NCT ID:** NCT06028438
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-15
- **Primary completion:** 2024-08-29
- **Final completion:** 2024-10-29
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06028438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06028438, "A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT06028438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*